Role Of Alendronate and Parathyroid Hormone in Postmenopausal Osteoporosis: A Randomized Clinical Trial

Abstract

Aim: To compare the role of Alendronate and Parathyroid Hormone in Postmenopausal Osteoporosis

Study Design: Randomized Clinical Trial

Place and duration: This study was conducted in Peoples University of Medical & Health Sciences Nawabshah, Pakistan from Jan 2019 to Jan 220

Methodology: Total 238 women with deficient bone mineral density in the hip or spine were examined by dual-energy X-ray absorption spectroscopy (DxA) and Quantitative CT (QCT) over the course of a year for bone mineral density. They were randomly allocated to alendronate, parathyroid hormone and both alendronate and parathyroid hormone (Combination therapy) groups. Individuals who were fasting were subjected to a blood test to search for indicators of bone turnover.

Result:  There was no statistically important alteration in the improvement of spinal bone mineral density between the parathyroid hormone and combination-therapy groups. There was an improve in trabecular bone volumetric density at the spine in all three groups, although it was approximately twice as great in the parathyroid hormone group. Only in the group taking parathyroid hormone did bone development rise significantly. Both the combined therapy and alendronate groups had a reduction in bone resorption.

Conclusion:  

There was no sign that parathyroid hormone and alendronate functioned together in a synergistic manner. When alendronate is used with parathyroid hormone, it's likely that changes in volumetric bone density, hip cortical volume, and indicators of bone turnover will occur, counteracting the parathyroid hormone's anabolic benefits. An extensive amount of fracture research must be conducted over an extensive period of time in order to discover any anti-resorptive medications may be utilized in combination with parathyroid hormone treatment.